Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

Linq Labs

Start a request
Advantage
Year Established:
2015
Website:
linqlabs.com
Headquarters:
Pune , MH , IN
Company Type:
Small Business (1-10M TTM Revenue)
Open Requests:
6
Certifications:

Linq Therapeutics Pvt Ltd. (Trade Name: Linq Labs ®) is an ISO 17025 certified and DSIR recognized niche research laboratory which has a Molecular Biology, Cell Biology, Serology and Microbiology lab facility in Pune, India.
Linq Labs has a state-of-the-art world class digitized and characterized retrospective biobank with access to over 10,000+ stored samples and a network of over 200+ partner hospitals in India for Prospective sample collection.

Linq Labs Bio-repository has an umbrella Institutional Review Board (IRB) approval for collecting human bio-material. We have experience of several studies including the ability to collect specialized samples such as PBMC isolation, collection using specialized tubes such as Streck, PaxGene etc.

Linq Labs is the sister insitution of JCDC (Jehangir Clinical Development Centre) which is a reputed CRO with experience of 250+ clinical projects including Phase I-IV clinical trials, validation studies, Real World Evidence studies etc.

Site Badges
Linq Labs
Taboot Street, Near JJ Garden, Camp Pune, MH, 411001 India
Linq Labs
Taboot Street, Pune , MH , 411001 India
Linq Therapeutics Pvt. Ltd
Taboot Street, Pune , MH , 411001 India

Get started

If your organization has a Scientist.com marketplace, you can log in here to order products and services directly.

If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here.

To order products instantly, request access below.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)

By signing up for this account you agree to the Terms of Service